P21 (Waf1/Cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: A preliminary study

Archives of Iranian Medicine

Volumn 13, Issue 3, 2010, Pages 235-242

  Taghavi, Noushin ^a   Biramijamal, Firouzeh ^a   Abbaszadegan, Mohammad Reza ^b   Khademi, Hooman ^c   Sotoudeh, Masoud ^c   Khoshbakht, Shahrouz ^a  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cigarette smoking; Esophageal squamous cell carcinoma; P21 polymorphism

Indexed keywords

PROTEIN P21;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; CODON; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRAN; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; IRAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES; RISK ASSESSMENT; SMOKING;

EID: 77953064453     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
3. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970 - 1990. Int J Cancer. 2002; 102: 271-274.
4. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and esophageal cancer risk. Int J Cancer. 2007; 121: 1643 - 1658.
5. Hiyama T, Tanaka S, Shima H, Kose K, Kitadai Y, Ito M, et al. Somatic mutation of mitochondrial DNA in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int JMol Med. 2003; 12: 169-174.
6. Kmet J, Mahboubi E. Esophageal cancer in the Caspian littoral of Iran: Initial studies. Science. 1972; 175: 846-853.
7. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian Cancer Registry. Br J Cancer. 1973; 28: 197-214.
8. Islami F, Kamangar F, Aghcheli K, Fahimi S, Sem-nani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancers in northeastern Iran. Br J Cancer. 2004; 90: 1402 - 1406.
9. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, et al. K-ras mutation in Helico-bacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer. 2002; 97: 562-566.
10. Muñoz N, Buiatti E. Chemoprevention of oesophageal cancer. IARC Sci Publ. 1996; (136): 27-33.
11. Brown LM Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, Schoenberg J, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol. 2001; 153: 114-122.
12. Nasrollahzadeh D, Kamangar F, Aghcheli K, So-toudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008; 98: 1857 - 1863.
13. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol Rep. 2003; 10: 1615-1623.
14. el-Deiry WS, Harper JW, O'Connor PM, Velcules-cu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994; 54: 1169 - 1174.
15. Harper JW, Adami GR, Wei N, Keyomarsi K, ElledgeSJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell. 1993; 75: 80-816.
16. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993; 366: 701-704.
17. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, et al. p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science. 1995; 267: 1024 - 1027.
18. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell. 1993; 4: 897-906.
19. Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005; 26: 1596 - 1602.
20. Roninson IB. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): association with cell senescence and tumour promoting activities of stro-mal fibroblasts. Cancer Lett. 2002; 179: 1-14.
21. Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Cell. 1993;72: 903-917.
22. Rastinejad F, Conboy MJ, Rando TA, Blau HM. Tumor suppression by RNA from the 3' untranslated region of a-Tropomyosin. Cell. 1993; 75: 1107-1117.
23. Fan H, Villegas C, Huang A, Wright JA. Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res. 1996; 56: 4366-4369.
24. Chen FY, Amara FM, Wright JA. Mammalian ri-bonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region. EMBO J. 1993; 12: 3977-3986.
25. Amara FM, Chen FY, Wright JA. Phorbol ester modulation of a novel cytoplasmic protein binding activity at the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA and role in message stability. J Biol Chem. 1994; 269: 6709-6715.
26. Amara FM, Hurta RA, Huang A, Wright JA. Altered regulation of message stability and tumor promoter-responsive cis-trans interaction of ribo-nucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells. Cancer Res. 1995; 55: 4503-4506.
27. Amara FM, Chen FY, Wright JA. Deining a novelcis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-b1 induced mRNA stabilization. Nucleic Acids? Res. 1995; 23: 1461 - 1467.
28. Wu MT, Wu DC, Hsu HK, Kao EL, Yang CH, Lee JM. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett. 2003; 201: 175-180.
29. Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995; 4: 1089 - 1092.
30. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21 (Waf1/Cip1) cyclin-dependent kinase inhibitor gene. Cancer. 1997; 79: 2424 - 2429.
31. Taghavi N, Nasrollahzadeh D, Merat S, Yazdanbod Hormazdi M, Sotoudeh M, et al. Epidemiology of upper gastrointestinal cancers in Iran: A sub site analysis of 761 cases. World J Gastroenterol. 2007; 13: 5367-5370.
32. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 2217 - 2224.
33. Quinones LA, Irarrazabal CE, Rojas CR, Orel-lana CE, Acevedo C, Huidobro C, et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl. 2006; 8: 349-355.
34. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kad-lubar FF, et al. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-trans-ferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev. 2000; 9: 551-556.
35. van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res. 1999; 59: 586-589.
36. Roth MJ, Dawsey SM, Wang G, Tangrea JA, Zhou Ratnasinghe D, et al. Association between GSTM1*0 and squamous dysplasia of the esophagus in the high risk region of Linxian, China. Cancer Lett. 2000; 156: 73-81.
37. Morita S, Yano M, Tsujinaka T, Akiyama Y, Tani-guchi M, Kaneko K, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer. 1999; 80: 685-688.
38. Butler WJ, Ryan P, Roberts-Thomson IC. Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol. 2001; 16: 631-635.
39. Rojas M, Cascorbi I, Alexandrov K, Kriek E, Au-burtin G, Mayer L, et al. Modulation of benzo[a] pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis. 2000; 21: 35-41.
40. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T.Polymorphisms of the CYP1A1 and GSTM1 geneinvolved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol. 1999; 35:191-196.
41. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis. 1999; 20: 1927 - 1931.
42. Shih CM, Lin PT, Wang HC, Huang WC, WangYC. Lack of evidence of association of p21WAF1/ CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000; 91: 9-15.
43. Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, et al. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12: 174-175.
44. Lai KC, Chen WC, Jeng LB, Li SY, Chou MC, Tsai FJ. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol. 2005; 31: 1135-1140.
45. Roh J, Kim M, Kim J, Park N, Song Y, Kang S, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 2001; 165: 59-62.
46. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 2004; 93: 499-505.
47. Popanda O, Edler L, Waas P, Schattenberg T, But-kiewicz D, Muley T, et al. Elevated risk of squa-mous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer.2007; 55: 25-34.
48. Kibel AS, Suarez BK, Belani J, Oh J, Webster R,Brophy-Ebbers M, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003; 63: 2033 - 2036.
49. Sepehr A, Kamangar F, Abnet CC, Fahimi S, Pour-shams A, Poustchi H, et al. Genetic polymorphisms in three Iranian populations with different risks of esophageal cancer, an ecologic comparison. Cancer Lett. 2004; 213: 195-202